New Kaiser Permanente study highlights importance of monitoring patients’ cardiovascular health both during and after treatment
Breast cancer patients who stay on cancer therapies that block estrogen for at least 5 years are more likely to be diagnosed with cardiometabolic health problems than patients who stay on these medications for a shorter period — but they are less likely to die from breast cancer, a new Kaiser Permanente study found.
The study, published in JNCI Cancer Spectrum, is one of the first to assess the relationship between use of anti-estrogen therapies to treat hormone-sensitive tumors and the likelihood of developing cardiometabolic risk factors or dying from breast cancer or other causes in the 10 years following a breast cancer diagnosis.

About 80% of women diagnosed with breast cancer have tumors that are hormone sensitive. The recommended treatment for these types of tumors includes taking an anti-estrogen therapy — typically tamoxifen or an aromatase inhibitor — daily for at least 5 years. However, side effects associated with these medications sometimes lead women to stop treatment early.
“Because some women prescribed these medications don’t take them for at least 5 years, we were able to look at the association between how long women stay on these therapies and the 10-year risk of developing certain cardiometabolic risk factors, like diabetes or hypertension,” said senior author Marilyn L. Kwan, PhD, a research scientist at the Kaiser Permanente Division of Research (DOR). “Studies have shown that some anti-estrogen therapies can increase risk for cardiovascular disease, and the cardiometabolic factors we studied are tied to heart disease risk.”
Focus on the heart
The new study included 8,365 postmenopausal Kaiser Permanente Northern California members enrolled in the Pathways Heart Study who were diagnosed with non-metastatic hormone-sensitive breast cancer between 2005 and 2013 and had been prescribed an aromatase inhibitor or tamoxifen after their breast cancer surgery.
The investigators reviewed the patients’ electronic medical records to determine if they had been diagnosed with high blood pressure, dyslipidemia (high levels of fat, cholesterol, or triglycerides), or diabetes, or had died of breast cancer or any other cause up to 10 years after their breast cancer diagnosis. They used the patients’ prescription refill records to determine how long they had stayed on an anti-estrogen therapy.
Overall, 42.7% of the women stayed on their anti-estrogen therapy for 5 or more years. About 12% stayed on their medication for 3 to 4 years, while another 12% took the medication 1 to 2 years. During the 10 years of follow-up, 23.3% of the women died, with 45.6% of the deaths due to breast cancer, 14.2% due to cardiovascular disease and 40.2% due to other causes.
The women who stayed on their anti-estrogen therapy for 5 years had an 8.8% higher absolute risk of developing high blood pressure, a 5.1% higher absolute risk of being diagnosed with high levels of fat, cholesterol, or triglycerides, and a 2.6% higher absolute risk of being diagnosed with diabetes over 10 years of follow up than the women who started anti-estrogen therapy but never consistently took it as prescribed.
The women who stayed on the anti-estrogen therapy for 5 years also had a 10.7% lower absolute risk of death from any cause and a 5.3% lower absolute risk of death from breast cancer after 10 years of follow up.

The type of anti-estrogen therapy was tied to cardiometabolic risk. Aromatase inhibitor use was associated with an increased risk of high blood pressure, high levels of fat, cholesterol, or triglycerides, or diabetes, while tamoxifen, was associated only with an increased risk of high blood pressure. The researchers said this is likely because the therapies work in different ways to block estrogen.
“Our study adds to what we know about the risks and benefits of anti-estrogen therapies,” said first author Jorge Ledesma, PhD, who conducted the research as a DOR Delivery Science Postdoctoral Research Fellow. “The next step is to take what we now know to identify the best ways to integrate cardiometabolic care into the long-term survivorship care of women who are taking or have taken tamoxifen or an aromatase inhibitor.”
Added Kwan: “Our previous studies have demonstrated that diet and exercise can improve cardiovascular outcomes in breast cancer survivors. For survivors who are on an anti-estrogen therapy, healthy eating and physical activity may play an even larger role in lowering their risk of developing cardiometabolic health problems and, in turn, cardiovascular disease.”
The study was funded by the National Cancer Institute.
Co-authors include Joshua Nugent, PhD, Cecile A Laurent, MS, and Janise Roh, MSW, MPH, of the Division of Research; Richard Cheng, MD, MSc, Samir R. Thadani, MD, and Raymond Liu, MD, of The Permanente Medical Group; Jennifer M. Specht, MD, and Heather Greenlee, ND, PhD, of the University of Washington; Sayan Dasgupta, PhD, and Allison Meisner, PhD, of the Fred Hutchinson Cancer Research Center.
###
About the Kaiser Permanente Division of Research
The Kaiser Permanente Division of Research conducts, publishes, and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. KPDOR seeks to understand the determinants of illness and well-being and to improve the quality and cost-effectiveness of health care. Currently, DOR’s 720-plus staff, including 73 research and staff scientists, are working on nearly 630 epidemiological and health services research projects. For more information, visit divisionofresearch.kp.org.





Comments (0)